Last reviewed · How we verify

NCT05955118

Hydrus Microstent as a Quality of Life Consideration

Status unknown Last updated 21 July 2023
What this trial tests

trial testing Hydrus Microstent in Open Angle Glaucoma in 38 participants. Status unknown.

Timeline
1 April 2023
Primary endpoint
1 April 2024
1 April 2024

Quick facts

Lead sponsorInSight Vision Center Medical Group, Inc
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment38
Start date1 April 2023
Primary completion1 April 2024
Estimated completion1 April 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

InSight Vision Center Medical Group, Inc

Who can join

18 and older, any sex, with Open Angle Glaucoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aims to identify if Hydrus microstent implantation in patients with open angle glaucoma (OAG) at the time of cataract surgery improves quality of life for patients and explore what quality of life factors motivate patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Hydrus Microstent

Trials testing the same drug.

Other recruiting trials for Open Angle Glaucoma

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05955118.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing